Impact of the COVID-19 pandemic on tuberculosis national reference laboratory services in the WHO European Region, March to November 2020.


Journal

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452

Informations de publication

Date de publication:
06 2021
Historique:
entrez: 18 6 2021
pubmed: 19 6 2021
medline: 24 6 2021
Statut: ppublish

Résumé

We assessed the impact of COVID-19 on diagnostic services for tuberculosis (TB) by national reference laboratories in the WHO European Region. Of 35 laboratories, 30 reported declines in TB sample numbers, amounting up to > 50% of the pre-COVID-19 volumes. Sixteen reported reagent or consumable shortages. Nineteen reallocated ressources to SARS-CoV-2 testing, resulting in an overall increase in workload, largely without a concomitant increase in personnel (n = 14). This poses a risk to meeting the 2025 milestones of the End TB Strategy.

Identifiants

pubmed: 34142651
doi: 10.2807/1560-7917.ES.2021.26.24.2100426
pmc: PMC8212594
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : World Health Organization
ID : 001
Pays : International
Organisme : FIC NIH HHS
ID : D43 TW007124
Pays : United States

Investigateurs

Ana Avellón (A)
Zamira Baydulloeva (Z)
Vladimir Chulanov (V)
Daniela Maria Cirillo (DM)
Dmitry Kireev (D)
Claudio U Köser (CU)
Stefan Niemann (S)
Ecaterina Noroc (E)
Roger Paredes (R)
Rob Schuurman (R)
Elina V Sevastyanova (EV)
Daniel Simões (D)
Alena Skrahina (A)
Maja Stanojevic (M)

Commentaires et corrections

Type : ErratumIn

Références

EClinicalMedicine. 2020 Oct 24;28:100603
pubmed: 33134905
Eur Respir J. 2021 Jan 5;57(1):
pubmed: 33184119
Int J Tuberc Lung Dis. 2021 Mar 1;25(3):167-170
pubmed: 33688804
Eur Respir J. 2020 Aug 13;56(2):
pubmed: 32513784
Emerg Infect Dis. 2020 Nov;26(11):2709-2712
pubmed: 32917293
Eur Respir J. 2020 Oct 1;56(4):
pubmed: 32703780
Euro Surveill. 2020 Nov;25(47):
pubmed: 33243354
Emerg Infect Dis. 2020 Nov;26(11):2549-2554
pubmed: 32956612

Auteurs

Florian P Maurer (FP)

National and WHO Supranational Reference Laboratory for Mycobacteria, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.
Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Natalia Shubladze (N)

National Reference Laboratory, National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia.

Gulmira Kalmambetova (G)

National TB Reference Laboratory, Bishkek, Kyrgyzstan.

Irina Felker (I)

Scientific department, Novosibirsk Tuberculosis Research Institute, Novosibirsk, Russia.

Giorgi Kuchukhidze (G)

Regional Office for Europe, World Health Organization, Copenhagen, Denmark.

Francis Drobniewski (F)

Infectious Diseases, Faculty of Medicine, Imperial College London, London, United Kingdom.

Askar Yedilbayev (A)

Regional Office for Europe, World Health Organization, Copenhagen, Denmark.

Soudeh Ehsani (S)

Regional Office for Europe, World Health Organization, Copenhagen, Denmark.
The named authors are members of the European Laboratory Initiative on TB, HIV and Viral Hepatitis core group. The additional members of the European Laboratory Initiative on TB, HIV and Viral Hepatitis core group are listed under Investigators.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH